12/27/2022 8:32:45 AM
PolarityTE Announces Entry Into LoI For Acquisition Of Company
11/10/2022 4:35:41 PM
PolarityTE Q3 Loss/share $0.47 Vs. Loss $0.37 Year Ago
11/9/2022 8:02:11 AM
PolarityTE Confirms Receipt Of $1.25/shr, Non-Binding Offer To Acquire The Company
9/8/2022 8:31:00 AM
PolarityTE Announces Resignation Of Jeff Dyer From Board
8/11/2022 4:09:47 PM
PolarityTE Q2 Loss/share $0.49 Vs. Loss $1.01 Year Ago
6/6/2022 8:17:40 AM
PolarityTE Announces $8 Mln Registered Direct And Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
5/16/2022 7:35:07 AM
PolarityTE Q1 Adj Loss/shr $0.10 Vs Loss/shr $0.11 Prior Year
5/13/2022 8:02:59 AM
PolarityTE Says FDA Granted Regenerative Medicine Advanced Therapy Designation To SkinTE
3/30/2022 7:36:40 AM
PolarityTE FY Loss Per Share $0.38 Vs Loss $1.16 Last Year
1/18/2022 8:02:32 AM
PolarityTE : FDA Approves IND For Pivotal Phase 3 Study Of SkinTE To Support Chronic Cutaneous Ulcer Indication